Angiogenesis Inhibitors: all 4,430 studies that test it
Page 45 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.
- SU5416 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00003720Phase 1
- Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's LymphomaCompletedNCT00003575Phase 2
- Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
- Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal CancerCompletedNCT00003439Phase 1
- Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell TransplantationStatus unknownNCT00003412Phase 1
- Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00003339Phase 2
- Interleukin-12 in Treating Patients With Advanced CancerCompletedNCT00003330Phase 1
- Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's DiseaseCompletedNCT00003210Phase 2
- Interleukin-12 in Treating Patients With Multiple MyelomaCompletedNCT00003149Phase 2
- Interleukin-12 in Treating Patients With Hematologic Cancers or Solid TumorsCompletedNCT00003107Phase 1
- Interleukin-12 in Treating Patients With Cancer in the AbdomenCompletedNCT00003046Phase 1
- Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the CervixCompletedNCT00003017Phase 2
- Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic MelanomaCompletedNCT00002952Phase 1/2
- A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAARTCompletedNCT00002392Not applicable
- Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002226Not applicable
- Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected PatientsCompletedNCT00002174Not applicable
- Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting SyndromeCompletedNCT00002157Not applicable
- A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting SyndromeCompletedNCT00002127Phase 2
- Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIVCompletedNCT00002104Phase 1
- Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial InfectionsCompletedNCT00001911Phase 1
- Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex InfectionCompletedNCT00001763Phase 1
- A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus ErythematosusCompletedNCT00001680Phase 2
- Pilot Study of Thalidomide to Treat Sjogren's SyndromeCompletedNCT00001599Phase 2
- Thalidomide to Treat Oral Lesions in HIV-Infected PatientsCompletedNCT00001524Phase 2
- A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate CancerCompletedNCT00001446Phase 2
- Treatment of Chronic Cryptosporidiosis in AIDS PatientsTerminatedNCT00001128Not applicable
- A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3CompletedNCT00000857Phase 1
- A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 InfectionCompletedNCT00000812Phase 1
- Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV InfectionCompletedNCT00000790Phase 2
- A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's SarcomaCompletedNCT00000763Phase 1